Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Myeloid 8Lymphoid 5Thoracic 4Head & Neck 2Gastrointestinal 2Sarcoma 1CNS 1

Conditions

Glioblastoma 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × ponatinib × CNS × Clear all
NCT02478164 2018-07-24

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Completed
17 enrolled 13 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡